| Literature DB >> 33529321 |
Floriane Petit1, Anthony Drecourt1, Michaël Dussiot1,2, Coralie Zangarelli1, Olivier Hermine1,2, Arnold Munnich1,3, Agnès Rötig1.
Abstract
Friedreich ataxia (FRDA) is a frequent autosomal recessive disease caused by a GAA repeat expansion in the FXN gene encoding frataxin, a mitochondrial protein involved in iron-sulfur cluster (ISC) biogenesis. Resulting frataxin deficiency affects ISC-containing proteins and causes iron to accumulate in the brain and heart of FRDA patients. Here we report on abnormal cellular iron homeostasis in FRDA fibroblasts inducing a massive iron overload in cytosol and mitochondria. We observe membrane transferrin receptor 1 (TfR1) accumulation, increased TfR1 endocytosis, and delayed Tf recycling, ascribing this to impaired TfR1 palmitoylation. Frataxin deficiency is shown to reduce coenzyme A (CoA) availability for TfR1 palmitoylation. Finally, we demonstrate that artesunate, CoA, and dichloroacetate improve TfR1 palmitoylation and decrease iron overload, paving the road for evidence-based therapeutic strategies at the actionable level of TfR1 palmitoylation in FRDA.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33529321 DOI: 10.1182/blood.2020006987
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113